德国人群房颤筛查的优化与成本效益
OBJECTIVE: Little is known on optimal screening population for detecting new atrial fibrillation (AF) in the community. We describe characteristics and estimate cost-effectiveness for a single timepoint electrocardiographic screening.…
要点
- 单次心电图筛查在中老年人群中新发房颤检出率为0.2%,65-74岁为0.5%。
- Nt-proBNP预筛未改善简单年龄切点的成本效益。
核心结论
- 在中老年人群队列中,单次筛查新发房颤检出率为0.2%,新发房颤者卒中与心衰风险显著。
- 筛查成本效益可能在65岁及以上人群中实现,简单年龄切点未因Nt-proBNP预筛而改善。
研究设计与样本
- 收集超过120项临床和生物标志物变量,包括Nt-proBNP、危险因素、症状和超声心动图变量。
主要发现
- 新发房颤者经典危险因素负担高,中位估计卒中风险为2.2%/年,10年心衰发生风险为21%。
- 模拟中成本对房颤检出率、治疗比例和口服抗凝药类型高度敏感。
- 当前场景下Nt-proBNP预筛不具备成本效益。
临床怎么用
- 可考虑对65岁及以上人群进行单次心电图房颤筛查以兼顾检出与成本效益。
- 不推荐使用Nt-proBNP作为生物标志物指导房颤筛查计划。
局限性
- 单次时间点筛查可能低估房颤检出率。
- 成本效益结果高度依赖模拟假设中的检出率、治疗比例和抗凝药类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Little is known on optimal screening population for detecting new atrial fibrillation (AF) in the community. We describe characteristics and estimate cost-effectiveness for a single timepoint electrocardiographic screening. METHODS: We performed a 12-lead ECG in the German population-based Gutenberg Health Study between 2007 and 2012 (n=15 010), mean age 55±11 years, 51% men and collected more than 120 clinical and biomarker variables, including N-terminal pro B-type natriuretic peptide (Nt-proBNP), risk factors, disease symptoms and echocardiographic variables. RESULTS: Of 15 010 individuals, 466 (3.1%) had AF. New AF was found in 32 individuals, 0.2% of the total sample, 0.5% of individuals aged 65-74 years and predominantly men (86%). The classical risk factor burden was high in individuals with new AF. The median estimated stroke risk was 2.2%/year, while risk of developing heart failure was 21% over 10 years. In the 65-74 year age group, the cost per quality-adjusted life-year gained resulting from a single timepoint screening was €30 361. In simulations, the costs were highly sensitive to AF detection rates, proportion of treatment and type of oral anticoagulant. Prescreening by Nt-proBNP measurements was not cost-effective in the current setting. CONCLUSIONS: In our middle-aged population cohort, we identified 0.2% new AF by single timepoint screening. There was a significant estimated risk of stroke and heart failure in these individuals. Cost-effectiveness for screening may be reached in individuals aged 65 years and older. The simple age cut-off is not improved by using Nt-proBNP as a biomarker to guide a screening programme.
引用
- Schnabel RB, Wallenhorst C, Engler D, et al. Refined atrial fibrillation screening and cost-effectiveness in the German population. Heart. 2021. PMID: 34376487. doi:10.1136/heartjnl-2020-318882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。